Current Hepatitis Reports

, Volume 5, Issue 2, pp 45–48 | Cite as

Hepatitis a vaccination



Hepatitis A virus is a globally prevalent hepatotrophic pathogen.Infection generally results in an acute,self-limiting illness but with the potential for significant morbidity and mortality in a susceptible population.Safe and effective vaccines are currently available in the United States and worldwide.Implementation of successful vaccination programs has allowed for favorable shif ts in the epidemiology of this disease.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Wasley A, Samandari T, Bell BP: Incidence of hepatitis A in the United States in the era of vaccination. JAMA 2005, 294:194–201. This article reports on the significant reduct ions in hepatitis A incidence post-implementat ion of t he US HAV vaccine program.PubMedCrossRefGoogle Scholar
  2. 2.
    Dagan R, Leventhal A, Anis E, et al.: Incidence of hepatitis A in Israel following universal immunizat ion of toddlers. JAMA 2005, 294:202–210. A report on the remarkable success in controlling hepatitis A infections through HAV vaccinat ions of a targeted population in Israel.PubMedCrossRefGoogle Scholar
  3. 3.
    LednarWM, Lemon SM, Kirkpatrick JW, et al.: Frequenc y of illness associated with epidemic hepatitis A virus infections in adults. Am J Epidemiol 1985, 122:226–233.PubMedGoogle Scholar
  4. 4.
    Berge JJ, Drennan DP, Jacobs RJ, et al.: The cost of hepatitis A infections in American adolescents and adults in 1997. Hepatology 2000, 31:469–473.PubMedCrossRefGoogle Scholar
  5. 5.
    Centers for Disease Control and Prevention:Summary of notifiable diseases,United States,1999.MMWR 1999,48:82–90.Google Scholar
  6. 6.
    Armstrong GL, Bell BP: Hepatitis A virus infections in t he United States:model-based estimates and implications for childhood immunization. Pediatrics 2002, 109:839–845.PubMedCrossRefGoogle Scholar
  7. 7.
    Shapiro CN, Coleman PJ, McQuillan GM, et al.: Epidemiology of hepat it is A:seroepidemiology and risk groups in the USA. Vaccine 1992, 10(Suppl 1):S59-S62.PubMedCrossRefGoogle Scholar
  8. 8.
    Centers for Disease Control and Prevention: Prevention of hepatitis At hrough active or passive immunization: recommendations of t he Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep 1999,48:1–37. A comprehensive review of HAV clinical features,sur veillance, transmission,and epidemiology,as well as extensive review of vaccine performance.Includes data and rationale for current ACIP vaccination guidelines.Google Scholar
  9. 9.
    Centers for Disease Control and Prevention:Hepatitis A vaccination coverage among children 24–35 months —United States,2003.MMWR Morb Mortal Wkly Rep 2005,54:141–144.Google Scholar
  10. 10.
    Bell BP: Hepatitis A vaccine. Semin Pediatr Infect Dis 2002, 13:165–173. An excellent in-depth review of HAV vaccine and epidemiology.PubMedCrossRefGoogle Scholar
  11. 11.
    Lemon SM, Binn LN: Serum neutralizing antibody response to hepatitis A virus. J Infect Dis 1983, 148:1033–1039.PubMedGoogle Scholar
  12. 12.
    McMahon BJ, Williams J, Bulkow L, et al.: Immunogenicity of an inactivated hepatitis A vaccine in Alaska Native children and Native and non-Native adults. J Infect Dis 1995, 171:676–679.PubMedGoogle Scholar
  13. 13.
    BalcarekKB, Bagley MR, Pass RF, et al.: Safet y and immunogenicit y of an inactivated hepatitis A vaccine in preschool children. J Infect Dis 1995, 171(Suppl 1):S70-S72.PubMedGoogle Scholar
  14. 14.
    Clemens R, Safary A, Hepburn A, et al.: Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis 1995, 171(Suppl 1):S44-S49.PubMedGoogle Scholar
  15. 15.
    Notice to readers:FDA approval of VAQTA ® (hepatitis A vaccine,inact ivated)for children aged =1 year.http:// /hepatitis /a/ m. Accessed October 29,2005.Google Scholar
  16. 16.
    Troisi CL, Hollinger FB,Krause DS, Pickering LK: Immunizat ion of seronegative infants with hepatitis A vaccine (HAVRI X;SKB):a comparative study of two dosing schedules. Vaccine 1997, 15:1613–1617.PubMedCrossRefGoogle Scholar
  17. 17.
    Piazza M, Safary A, Vegnente A, et al.: Safety and immunogenicity of hepatitis A vaccine in infants:a candidate for inclusion in the childhood vaccination programme. Vaccine 1999, 17:585–588.PubMedCrossRefGoogle Scholar
  18. 18.
    Letson GW, Shapiro GN, et al.: Effect of maternal antibody on immunogenicity of hepatitis A vaccine in infants. J Pediatr 2004, 144:327–332.PubMedCrossRefGoogle Scholar
  19. 19.
    Dagan R, Amir J, Mijalovsky A, et al.: Immunization against hepatitis A in thefirst year of life:priming despite the presence of maternal antibody. Pediatr Infect Dis J 2000, 19:1045–1052.PubMedCrossRefGoogle Scholar
  20. 20.
    Werzberger A, Mensch B, Kuter B, et al.: A controlled trial of a for malin-inact ivated hepatitis A vaccine in healthy children. N Engl J Med 1992, 327:453–457.PubMedCrossRefGoogle Scholar
  21. 21.
    Innis BL, Snitbhan R, Kunasol P, et al.: Protection against hepatitis A by an inactivated vaccine. JAMA 1994, 271:28–34.CrossRefGoogle Scholar
  22. 22.
    Dominguez A, Salleras L, Carmona G, Batalla J: Ef fectiveness of a mass hepatitis A vaccination program in preadolescents. Vaccine 2003, 21:698–701.PubMedCrossRefGoogle Scholar
  23. 23.
    Van Herck K, Van Damme P: Inactivated hepatitis A vaccine-induced antibodies:follow-up and estimates of long-term persistence. J Med Virol 2001, 63:1–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Wiens B, Bohidar N, Pigeon J, et al.: Duration of protection from clinical hepatitis A disease after vaccination with VAQTA. J Med Virol 1996, 49:235–241.PubMedCrossRefGoogle Scholar
  25. 25.
    Niu MT, Salive M, Krueger C, et al.: Two-year review of hepatitis A vaccine safet y:dat a from the Vaccine Adverse Event Reporting System (VAERS).Clin Infect Dis 1998, 26:1475–1476.PubMedCrossRefGoogle Scholar
  26. 26.
    Merck &Co.:VAQTA ® (hepat it is A vaccine,inact ivated). In Physicians’ Desk Reference, edn 51.Mont vale, NJ:Medical Economics Co.;1997:1805–1807.Google Scholar
  27. 27.
    SmithKline Beecham Biologicals:HAVRI X ® (hepatitis A vaccine,inactivated).In Physicians ’ Desk Reference,,edn 51. Montvale,NJ:Medical Economics Co.;1997:2663–2665.Google Scholar
  28. 28.
    Kemper CA, Haubrich R, Frank I, et al.: Safety and immunogenicity of hepatitis A vaccine in human immunodeficiency virus-infected patients:a double-blind, randomized,placebo-controlled trial. J Infect Dis 2003, 187:1327–1331.PubMedCrossRefGoogle Scholar
  29. 29.
    Bryan JP, Nelson M: Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulinor hepatitis A vaccines. Arch Intern Med 1994, 154:663–668.PubMedCrossRefGoogle Scholar
  30. 30.
    Vento S, Garofano T, Renzini C, et al.: Fulminant hepatitis associated with hepatitis A virus superinfect ion in patients with chronic hepatitis. C.N Engl J Med 1998, 338:286–290.CrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  1. 1.UAB Liver CenterUniversity BoulevardBirminghamUSA

Personalised recommendations